Lexeo Therapeutics (LXEO) Change in Accured Expenses (2022 - 2026)

Lexeo Therapeutics has reported Change in Accured Expenses for 5 years, with the latest figure at -$1.1 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 147.17% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.9 million (down 536.95% YoY) and the FY2025 annual result came in at -$4.4 million, down 232.02% from the prior year.
• Change in Accured Expenses eased to -$1.1 million in Q1 2026 per LXEO's latest filing, from -$619000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.3 million in Q3 2024 and troughed at -$7.1 million in Q2 2025.
• A 5-year average of -$70500.0 and a median of -$763500.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 317.16% in 2024, down 421.63% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$908000.0 in 2022, then sank by 133.48% to -$2.1 million in 2023, then increased by 9.34% to -$1.9 million in 2024, then soared by 67.79% to -$619000.0 in 2025, then slumped by 76.41% to -$1.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.1 million, -$619000.0, and $996000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.